Pfizer, Inc. · NYSE:PFE
Pfizer — 2010 Annual Credit Suisse Healthcare Conference
19 slides from Pfizer's conference presentation, Nov 10, 2010
Slide 1: Pfizer Primary Care Business
Pfizer Primary Care Business November 10, 2010 1
Slide 2: Pfizer Primary Care
Pfizer Primary Care Olivier Brandicourt President and General Manager Primary Care Business Unit November 10, 2010
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information ● This presentation includes forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2009 A
Slide 4: Agenda
Agenda ● The Pfizer Primary Care Business Unit ● The Global Primary Care Market ● Pfizer’s Primary Care Business Unit Plan ● Pfizer’s Performance Around the World 4
Slide 5: Primary Care: The Largest of Pfizer's Nine Business Units
Primary Care: The Largest of Pfizer’s Nine Business Units Nine Diverse Businesses Supported by an Integrated Research & Development Organization Biopharmaceutical Businesses Primary Specialty Care Oncology Established Emerging Care Products Markets Diversified Businesses Consumer Animal Health Capsu
Slide 6: Primary Care: Pfizer Leads in a Market with Continued Opportunity
Primary Care: Pfizer Leads in a Market with Continued Opportunity Branded PC Market is Still Expected to Be $1251 Billion in 2015 ● Pharmaceutical industry research continues in Primary Care in areas not satisfied by generics About 1,400 Primary Care molecules in development today 70%2 increase
Slide 7: Primary Care Transforming Globally, Becoming the Hub of Care
Primary Care Transforming Globally Becoming the Hub of Care Emerging Ongoing Traditional Employer Gov’t Social Media Patient Patient Group KOL Practice KOL Patient HCP HCP KOL HCP Payer Payer Pharmacy Share of Voice Complex Customer Influence Integrated Partnership Model Model Model ● Health care st
Slide 8: A Three-Part Plan for Action
A Three-Part Plan for Action 1 2 3 Adapt & Size Build Transform 8
Slide 9: Size: Ensure Our Cost Structure is Aligned with Revenues
Size: Ensure Our Cost Structure is Aligned with Revenues Total Pfizer Cost Reduction Target of $4–$5 Billion from 2009–2012* Primary Care – Major Contributor ● Sized Primary Care field forces around the world for post-Lipitor LOE ● Using contract resources to maximize flexibility ● Established regio
Slide 10: Adapt & Transform: Meeting the Challenge
Adapt & Transform: Meeting the Challenge Market Challenges Pfizer Action ● Transformation of Primary Care go-to- Restricted ● Restrictions on access market model Physician Access ● Prefers tailored communication ● Multi-channel customer interaction ● Customer Relationship Management ● Pricing pressu
Slide 11: Build: PCBU Portfolio Aligns Well with Areas of Opportunity
Build: PCBU Portfolio Aligns Well with Areas of Opportunity Primary Care Treatment Well-Being Simple / Low-Risk Chronic / High-Risk Consumer-focused Routine Treatment for Costly, More Difficult to Solutions Otherwise Healthy Patients; Manage Patients/Conditions Generic Medicines Erectile Dysfunction
Slide 12: Build: Pfizer's Strength in Pain Management
Build: Pfizer’s Strength in Pain Management ● Pending acquisition of King Pharmaceuticals: Branded Prescription Products 2009 Sales: $1.2 billion ● King branded pharmaceutical portfolio includes: ● Flector Patch, strong complement to Celebrex ● Avinza, a once-daily morphine treatment for moderate to
Slide 13: Build: Eliquis (apixaban) Development Timeline Accelerated
Build: Eliquis (apixaban) Development Timeline Accelerated Market Opportunity Driven by Unmet Rolling Atrial Fibrillation (AF) Needs of Patients, Physicians Submission Underway rivaroxaban dabigatran Eliquis AF Eliquis AF 2010 2011 2012 EXPANSE Clinical Program ~60,000 Patients in 45 Countries Strok
Slide 14: Tanezumab: Phase 3 Data in Osteoarthritis of the Hip vs. Placebo
Tanezumab: Data from Phase 3 Study Demonstrate Superior Efficacy in Patients with Osteoarthritis of the Hip vs. Placebo Tanezumab ● Randomized, double-blind, placebo controlled study in 621 patients latebreaker at ACR ● Superior efficacy of tanezumab at all doses (2.5, 5 and 10 mg) vs. placebo for a
Slide 15: A Strategy That Delivers: US Portfolio Management
A Strategy That Delivers: US Portfolio Management Early Mid-Cycle Mature ● Leverage insights ● Improved DTC ● Continue improving ● Position for for depression efficiency trend post-LOE ● Will file for ● Rollout of COPD/ ● Growing ● Targeting high-risk vasomotor CVD studies fibromyalgia, patients sym
Slide 16: A Strategy That Delivers: Leveraging Growth in Japan
A Strategy That Delivers: Leveraging Growth in Japan ● Sell 3 of the top 5 products Rank Company Sales Share (MM Yen) ● Proven ability to successfully 1 Takeda 530,537 6.0% enter new markets for Pfizer 2 Pfizer* 528,476 5.9% Lyrica: July postherpetic neuralgia approval, 3 Daiichi Sankyo 491,671 5.
Slide 17: A Strategy That Delivers: Europe Performing Above Market Through Economic Crisis
A Strategy That Delivers: Europe Performing Above Market Through Economic Crisis France Germany Italy Spain UK ● Requests yearly ● Price freeze 8/2009 – ● Product level price ● Reference price ● Rx pricing unchanged €400m savings 12/2013 renegotiation cheapest comparator ● Reinforcing generic ● Up €
Slide 18: Winning Through Well-Differentiated Medicines, Efficient Management and Commercial Innovation
Winning Through Well-Differentiated Medicines, Efficient Management and Commercial Innovation Differentiated Medicines Efficiency and Effectiveness Commercial Innovation Environment Emerging Ongoing Traditional Integrated Partnership Model Complex Customer Influence Share of Voice Model Model Engagi
Slide 19: Thank You
Thank You 19
Pfizer — 2010 Annual Credit Suisse Healthcare Conference on 6ix